<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456403</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN-002</org_study_id>
    <nct_id>NCT01456403</nct_id>
  </id_info>
  <brief_title>Histological Validation Of Carotid Plaque Composition In Preoperative Imaging</brief_title>
  <official_title>Histological Validation Of Carotid Plaque Composition In Preoperative Imaging Of Patients Scheduled For Carotid Endarterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled for carotid endarterectomy undergo preoperative imaging to assess
      vulnerable plaque. The imaging modalities include (in various combinations at different study
      sites) 3-dimensional ultrasound, PET/CT imaging with fluorodeoxyglucose, MRI (3T)with
      gadolinium, and contrast ultrasound for assessment of neovascularity of plaques. At surgery
      the carotid endarterectomy is carried out with en bloc removal of the specimen, which is
      scanned and stained and assembled into 3D histology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Patients will undergo 3D U/S and at least one other imaging method,
      PET/CTA or MRI, preoperatively. At some sites, some patients will also have an ultrasound
      with microbubbles. Following surgery, the carotid specimens will be transported to a central
      pathology lab for microcomputed tomographic imaging and further study.

      At some sites patients will have a follow-up 3D U/S approximately 1 year after surgery to
      determine progression of plaque.

      CAIN-2 sub-studies:

      Eligible patients may be enrolled into one of the following sub-studies:

        1. CAIN-2 NaF pilot Characterizing Atherosclerotic Plaque with Sodium Fluoride Positron
           Emission Tomography- A Sub-Study of the Canadian Atherosclerosis Imaging Network (CAIN
           Project 2), - patients undergo sodium fluoride (NaF) PET/CT with CTA instead of FDG
           PET/CT preoperatively. All other imaging and study procedures are carried out as per the
           CAIN-2 study.

           Recruitment for this pilot study is complete.

        2. CAIN-2B Atherosclerotic plaque imaging using NaF and FDG imaging: Validation and
           Evaluation of Disease Progression. A sub-study of the Canadian Atherosclerosis Imaging
           Network (CAIN-2) Histopathology Validation study - patients undergo both NaF and FDG
           PET/CT preoperatively. All other imaging and study procedures are carried out as per the
           CAIN-2 study.

      A total of 45 patients will be enrolled in this sub-study. Eligibility criteria for the
      sub-studies is identical to the CAIN-2 criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic validation of preoperative imaging of vulnerable plaque</measure>
    <time_frame>Cross-sectional</time_frame>
    <description>3D histological images registered to the preoperative images of carotid plaques will be used to validate imaging features of plaque such as thin cap, intraplaque hemorrhage, large lipid core and inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of cardiovascular events</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence of stroke, cardiovascular death, myocardial infarction or revascularization procedures by imaging features of vulnerable plaque in the baseline images</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Carotid Stenosis</condition>
  <arm_group>
    <arm_group_label>Carotid endarterectomy patients</arm_group_label>
    <description>Patients scheduled for clinically indicated carotid endarterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Histological validation</intervention_name>
    <description>3D ultrasound, PET/CT, MRI, contrast ultrasound</description>
    <arm_group_label>Carotid endarterectomy patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Histological sections
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for carotid endarterectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for carotid endarterectomy; provided informed consent

        Exclusion Criteria:

          -  Those not eligible for some of the imaging modalities (for example, metal in body,
             renal dysfunction) are excluded from MRI imaging or CT angiography
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. David Spence, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Robarts Research Institute, University of Western Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W77</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.canadianimagingnetwork.org/</url>
    <description>CAIN website</description>
  </link>
  <link>
    <url>http://www.imaging.robarts.ca/SPARC/</url>
    <description>Stroke Prevention &amp; Atherosclerosis Research Centre</description>
  </link>
  <reference>
    <citation>Does Glucose Corrected [18F]fluorodeoxyglucose Uptake in Human Carotid Plaque Relate to the Extent of Inflammation on Immunohistology? Cocker M.S., Spence J.D., Hammond R., Mc Ardle B., deKemp R., Brennan J., Lum C., Yerofeyeva Y., Karavardanyan T., Adeeko A., Youssef G., Hill A., Stotts G., Renaud J.M., Alturkustani M., Hammond L., DaSilva J., Tardif J.C. and Beanlands R. American Heart Association Scientific Sessions. Los Angeles, United States. November 3 - 7, 2012. Circulation 2012: 126: A17612.</citation>
  </reference>
  <reference>
    <citation>Immunohistochemical Validation of [18F]-fluorodeoxyglucose as a Novel Biomarker of Inflamed Vulnerable Carotid Plaque: A Sub-study of the Canadian Atherosclerosis Imaging Network (CAIN). Cocker M.S., Mc Ardle B., deKemp R., Lum C., Youssef G., Hammond R., Yerofeyeva Y., Karavardanyan T., Adeeko A., Hill A., Stotts G., Sharma M., Renaud J.M., Brennan J., Alturkustani M., Hammond L., DaSilva J., Tardif J.C. Spence J.D., and Beanlands R. Canadian Cardiovascular Congress 2012. Toronto, Canada. October 26 - 31, 2012. Canadian Journal of Cardiology 2012: 28(5): S162.</citation>
  </reference>
  <results_reference>
    <citation>Cocker MS, Mc Ardle B, Spence JD, Lum C, Hammond RR, Ongaro DC, McDonald MA, Dekemp RA, Tardif JC, Beanlands RS. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol. 2012 Dec;19(6):1211-25. doi: 10.1007/s12350-012-9631-9. Review.</citation>
    <PMID>23073913</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>J. David Spence</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Carotid</keyword>
  <keyword>endarterectomy</keyword>
  <keyword>vulnerable plaque</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>MRI</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

